On Pfizer’s initiative to return clinical trial data to patients

 I was delighted to read the recent news from Pfizer announcing the launch of their Participant Data Return, which will return individual data to patients at scale. This approach is welcome. It will mean patients from the US will receive a summary of their data, in a visual, easily understood format, approximately 12 months after study completion.